Objective: Following Porphyromonas gingivalis infection in mice, the efficacy of vaccination by recombinant and native RgpA in modulating the early local antiinflammatory and immune responses and periodontal bone loss were examined.
Periodontitis is a bacterially induced chronic inflammatory disease, which results in the destruction of the dental attachment apparatus, leading to tooth loss (1) . Evidence suggests that Porphyromonas gingivalis, a gramnegative anaerobic bacterium, is closely associated with periodontal disease in humans (2, 3) . The subgingival infection stimulates various innate and adaptive immune responses, which include the secretion of proinflammatory cytokines such as interleukin (IL)-1b, IL-6, IL-11, IL-17, interferon-c and tumor necrosis factor (TNF)-a (4). In contrast, the dominant anti-inflammatory response, which was thought to protect the periodontal tissues from destruction by bacterial infection (5) , is characterized by IL-4, IL-10, IL-12, IL-13 and IL-18 secretion (4) .
To evade the host's immune response, P. gingivalis has developed a variety of virulence factors, which include gingipains. Gingipains, a group of cysteine proteases common to all P. gingivalis strains, consist of two arginine-specific proteases (Arggingipains [Rgps] ) and lysine-specific protease (Lys-gingipain [Kgp] ).
Gingipains alter intrinsic immunity by degrading defensins (6) , complement components (7) and cytokines (8, 9) thereby disrupting bacterial phagocytosis (10) . They inhibit adaptive immunity by cleaving various Tcell receptors (11, 12) , and stimulate the expression of protease-activated receptors in T cells (13) . These activities play a critical role in the induction of cytokine responses and the establishment of chronic inflammation in periodontitis and stimulating the expression of protease-activated receptors critical for inducing cytokine responses responsible for chronic inflammation (14) . Gingipains also have the ability to proteolytically inactivate cytokines (8, 9) , and stimulate IL-6 production by oral epithelial cells. Gingipains also stimulate proinflammatory cytokines from oral epithelial cells (15) and gingival fibroblasts (16) .
The Rgps are encoded by two genes, rgpA and rgpB, and Kgp is encoded by a single gene, kgp (17) . The mature forms of RgpA and Kgp proteins possess both a catalytic and a hemagglutinin domain, while RgpB is composed of only a catalytic domain (18) . The hemagglutinin domain of RgpA and Kgp is further subdivided into four individual adhesion domains (A1-A4) (19, 20) . The adhesin A1 encompasses several sequential motives interacting with the host systems while adhesin A2 constitutes the hemoglobin-binding domain playing a role in heme acquisition by P. gingivalis (21) .
As major virulent factors and important housekeeping enzymes that are expressed on the cell surfaces of all P. gingivalis strains with more than 98% identity (21) , gingipains have been suggested as candidate antigens for a vaccine against P. gingivalis. This contention was strongly supported by animal studies showing that immunization with purified or recombinant gingipains protects against subcutaneous challenge, significantly reduces alveolar bone loss and P. gingivalis colonization, and induces an anti-inflammatory immune response following oral infection (22) (23) (24) . Thus, the next steps in vaccine development ought to involve the identification and testing of peptides derived from gingipains as antigens for immunization. Although it was inferred that the adhesion/hemagglutinin domain might be a functionally important target for the host-specific immune response to P. gingivalis in periodontal disease, only one study systematically examined the efficiency of immunization with individual recombinant adhesion domains of gingipains to protect against P. gingivalis infection in the murine lesion model (25) . However, there is no investigation assessing immunization with individual domains in the experimental periodontitis model.
The aims of this study were: 10 CFU/mL (26) . Heat-killed P. gingivalis was prepared by incubating the bacteria at 80°C for 10 min (27) .
Purification of gingipains
High molecular mass arginine-specific gingipain A (95 kDa; native RgpA) containing adhesion domains A1-A4 was purified from P. gingivalis HG66 after cultivation for 48 h. Briefly, proteins in the culture supernatant were precipitated with acetone, the precipitated was dissolved in a gel filtration buffer (20 mM Bis-Tris, 150 mM NaCl, 5 mM CaCl 2 , 0.02% NaN 3 , pH 6.8), solution clarified by ultracentrifugation (100,000 g, 60 min, 4°C) and applied on the Sephadex G-150 (Sigma-Aldrich, St. Louis, MO, USA). HRgpA was eluted from this column at a protein peak corresponding to 150-200 kDa. The fractions containing HRgpA activity were pooled and subjected to affinity chromatography on Arg-Sepharose as described earlier (18, 28) . Protein concentration was determined using the bicinchoninic acid-based BCA Protein Assay Kit (Bio-Rad, Hercules, CA, USA) with bovine albumin as a standard and purity of the enzyme was checked by sodium dodecyl sulfate-polyacrylamide gel electrophoresis in a 10% Tricine gel. Obtained in this manner, RgpA is a non-covalent complex of a catalytic 50 kDa domain with hemagglutinin-adhesin domains (18) . The complex is stable for days at room temperature, for months at +4°C and for years if frozen and neither decrease of activity nor proteolytic degradation of any component of the complex was evident after storage. The amount of the active enzyme was determined by active-site titration using Phe-ProArg-chlormethyl ketone (FPR-cmk), a highly effective irreversible inhibitor reacting with Rgp with the equimolar stoichiometry (29) . The concentration of fully activated gingipain with cysteine was calculated from the amount of inhibitor needed for complete inactivation of the proteinase. Thus, the concentration of RgpA indicated in this paper is represented as those of active gingipain.
Recombinant RgpA peptide synthesis
The RgpA adhesin domain, G 721 -R 1262 (rec 70 kDa RgpA) containing the adhesion domains A1 and A2 was synthesized and expressed as described previously (19) . The identities of the recombinant proteins were confirmed by western blotting, with the use of a specific antibody to P. gingivalis proteins, and by automated N-terminal sequencing.
Bacterial procedures
Immunization and early local infection model (intrachamber model)-All experimental protocols were approved by the Institutional Animal Care and Ethics Committee.
To evaluate the effect of immunization with native RgpA on the early local immune response, we used the mouse subcutaneous chamber model (10) . Briefly, two titanium coil chambers were inserted subcutaneously into the dorsolumbar region of each of the anesthetized BALB/c female mice (n = 8 for each group), aged 5-6 wk. One week before and 1 wk after chamber implantation, the animals were immunized subcutaneously with 100 lL of either native RgpA (15 lg) (test group), heat-killed P. gingivalis strain 53,977 (2.5 9 10 8 CFU) (positive control), adjuvant alone or saline (negative controls). Each antigen was emulsified in alum. Two weeks following chamber implantation, all four groups were infected by means of intrachamber injection of P. gingivalis (5 9 10 8 CFU in 100 lL of PBS). Exudates from both chambers of each mouse were collected at baseline (immediately before the intrachamber infection), at 2 h, 48 h and 4 d postinfection. Each chamber was sampled once at each time point and the individual mouse was used as the unit of analysis. The exudates were centrifuged for 10 min at 290 g. The supernatants were collected and stored at À70°C until they were analyzed.
Immunization and experimental periodontitis model-Female BALB/c mice, aged 5-6 wk, were immunized subcutaneously with 100 lL of either 50 lg of the 70 kDa recombinant RgpA peptide (recRgpA) in alum (test group), or 2.5 9 10 8 CFU of heat-killed P. gingivalis strain 53,977 (in alum) (positive control), at 3, 2 and 1 wk before oral infection. The infection was carried out as described previously (30) . In brief, all animals were given sulfamethoxazole/trimethoprim (0.08% and 0.016% respectively) in drinking water, ad libitum for 10 d. Three days after the withdrawal of antibiotics, the animals were infected with P. gingivalis 53,977 or vehicle only (5 9 10 10 CFU/mL in 0.2 mL of PBS and 2% carboxymethylcellulose). The process was repeated three times, once every other day. Serum samples were obtained preinfection and postinfection for analysis of specific anti-P. gingivalis IgG1 and IgG2a. Forty-six days after the first infection, the mice were killed (using CO 2 ) , and hemi-maxillae were collected and prepared for bone loss measurements using the micro-computerized tomography technique to allow quantification of residual supportive bone volume as previously described (31) .
Analysis of cytokines-The presence of TNFa, IL-1b, IL-4 and IL-10 in the chamber exudates was determined using enzyme-linked immunosorbent assay, as previously described (30) . The assays were based on antibody pairs matched for enzyme-linked immunosorbent assay.
Analysis of serum anti-P. gingivalis IgG titers-Six weeks after immunization, blood was drawn from the mice and the sera were stored at À80°C. Ninetysix-well plates were coated overnight at 4°C with 1 lg of P. gingivalis lysate/ well in 0.1 M bicarbonate buffer (pH 9). The plates were washed twice with PBS-0.02% Tween 20 and blocked with PBS 10% fetal bovine serum (2 h at room temperature). Subsequently, mouse serum samples diluted serially in PBS were added to the wells for 3 h incubation at room temperature. This was followed by four washes in PBS-0.02% Tween 20 and the addition of antimouse peroxidase-conjugated IgG1 and IgG2a antibodies. After incubation for 2 h at room temperature, the plates were washed five times and 100 lL/well of TMB solution was added for 5 min followed by the addition of 100 lL TMB stop solution. Absorption was read at 450 nm using an iMARK microplate reader (Bio-Rad).
Data analysis
Data analysis was performed using a statistical software package. One-way analysis of variance was used to test the significance of the differences between the treated groups. When significance was established, the intergroup differences were tested for significance by ttest with the Student-Newman-Keuls method correction for multiple testing. The level of significance was determined at p < 0.05. All results are presented as means AE SEM.
Results

Local inflammation (intrachamber model)
Intrachamber cytokine levels following immunization with whole bacteria or native RgpA-Two hours post-infection, IL-1b levels peaked in the P. gingivalis, RgpA and adjuvant groups. At 4 d postinfection, a significant decrease in IL-1b levels was observed only in the RgpA-immunized group after 4 d (Fig. 1A) .
TNF-a levels were minimal and peaked at 2 h postinfection in all four infected groups without significant differences between groups. At 48 h and 4 d, cytokine levels dropped, with no significant differences between all groups (Fig. 1B) .
IL-4 levels peaked at 2 h postinfection only in the RgpA-immunized group, while decreased levels were observed in the heat-killed P. gingivalis-, adjuvant-and saline-immunized groups. At 48 h and 4 d, IL-4 levels were significantly higher only in the RgpA-immunized group (Fig. 1C) .
IL-10 levels peaked at 2 and 48 h without significant differences between the immunized groups (Fig. 1D ).
Experimental periodontitis model
Alveolar bone loss following immunization with recRgpA-Owing to the observed ability of immunization with purified native RgpA to modulate the host response we were interested in examining the efficacy of vaccine containing recRgpA peptide in preventing the clinical outcome of oral infection with P. gingivalis in mice. Our data show that mice immunized with the recRgpA peptide (test group) displayed significantly lower bone loss compared to the non-immunized-infected group (negative control) and the level of protection was similar, with no significant differences compared to the heat-killed P. gingivalis-immunized group (positive control) (Fig. 2) .
Antibody response-As the type of Tcell response is reflected in the IgG specificity response (IgG1 for T-helper [Th]2 cells, IgG2a for Th1) (32,33), we examined whether the antibody response against P. gingivalis was different after immunization with the recRgpA. Immunization with whole cell P. gingivalis induced significantly higher levels of both IgG subtypes compared to recRgpA vaccine or sham vaccine. Oral infection did not affect serum IgG1 or IgG2a titers in this group (Fig. 3) . Immunization with recRgpA induced serum titers of IgG1, but not IgG2a (Fig. 3A and  3C ). The IgG1 titers in this group were significantly higher compared to the sham-infected group, and significantly lower compared to the P. gingivalis-immunized mice. Following infection (Fig. 3B and 3D) , the IgG1 and IgG2a titers increased significantly in the non-immunized mice.
Discussion
Gingipains are major virulent factors that expressed on the cell surfaces of all P. gingivalis strains with more than 98% identity in the amino acid sequence (21) . As such, gingipains have been suggested as candidate antigens for vaccines. In the first part of the present study, we examined the ability of immunization with purified native RgpA to modulate the early local immune response. The results demonstrate that immunization of mice with native RgpA has the ability to shift the early local immune response toward an anti-inflammatory response (Fig. 1) . As noted previously (23), we found that IL-4 is the prominent cytokine that protects from both inflammation and alveolar bone loss. We have observed that immunization with native RgpA reduces IL-b levels. This may explain why both the present study ( Fig. 2) and previous studies have demonstrated the ability of immunization with RgpA or RgpAKgp adhesion complex to protect against alveolar bone loss following oral infection (24, 34) . IL-b has the ability to stimulate degrading proteinases and induce osteoclastogenesis leading to bone loss (35) . These results are reinforced by those from previous studies, which demonstrated that RgpA plays a central role in P. gingivalis pathogenicity (6,7,10) and can be used as an antigen in immunization against experimental periodontitis (22, 23) . In light of all these observations, we decided to focus on the ability of RgpA to act as an immunogen against P. gingivalis-induced infection in the context of experimental periodontitis in mice. Previous studies have shown that immunization with purified gingipains reduces P. gingivalis colonization (23, 24) . It also has the ability to affect the host immune response (10, 22, 23) and protect against a P. gingivalis challenge in the chamber infection model (36) , the murine lesion model (25) and experimental periodontitis following oral infection (23, 24, 34, 36) . Unlike these previous studies, we decided to test the effect of immunization with a recombinant peptide derived from the rgpA gene. Although recombinant peptides are different from purified proteins due to post-translational changes, the use of recombinant proteins as antigens in vaccines has several advantages. These include the elimination of the need to cultivate the pathogen, and the ability to avoid vaccines containing live attenuated and inactivated or killed microorganisms (37) . Of note, the RgpA-Kgp complexes contain a large glucan moiety thought to be an anionic lipopolysaccharide covalently decorating gingipains (38) (39) (40) . Nevertheless, the immune response elicited by complexes was similar to that elicited by polypeptide chain alone of domains A1 and A2 of RgpA. This argues against contribution of an anionic lipopolysaccharide to induction of protective antibodies by immunization with whole P. gingivalis cells.
Using the oral infection model (30), we tested the efficiency of immunization with a 70 kDa recombinant peptide, containing the A1 and A2 domains of the adhesion part of RgpA (G 721 -R 1262 ) in protecting mice from experimental periodontitis following oral infection with P. gingivalis. Our results demonstrate that this immunization protocol partially prevented the induced bone loss, similarly to the protection achieved with a whole bacteria vaccine (Fig. 2) . To the best of our knowledge, this is the first work demonstrating the efficacy of immunization with a recombinant RgpA peptide in preventing bone loss in a murine model of periodontitis. These results are in accordance with the results of previous studies (23, 24, 34) . The importance of the humoral response to the severity of human periodontal disease has been investigated in many studies (41, 42) . Some studies have shown that elevated serum levels of anti-P. gingivalis IgG have been directly linked to disease severity. However, others have found that the levels of antibodies in the gingival crevicular fluid are inversely related to the number of organisms at the site of sampling (43, 44) . In a clinical study, anti-P. gingivalis IgG levels at periodontitis sites were found to be lower than at gingivitis sites in the same subjects, suggesting that a failure of local antibody production may contribute to the transition from gingivitis to periodontitis (45) . Gibson et al. showed a correlation between IgG titer to P. gingivalis' RgpA and opsonic uptake of P. gingivalis by PMNs in patients with aggressive periodontitis (46) .
RgpA and opsonic uptake of P. gingivalis by polymorphonuclear cells in patients with aggressive periodontitis. These results demonstrate that RgpAspecific antibodies are critical to providing immunological support for opsonization of P. gingivalis by the host (46) . O'Brien-Simpson et al. (47) showed that the sera of patients with periodontal disease possess gingipainspecific IgG predominantly of the subtype IgG4, and a negative correlation between serum IgG4 levels and oral bone loss was shown to exist. In light of the above, the ability of vaccines to induce a direct humoral response against P. gingivalis and P. gingivalis' gingipains together with the manner in which this response affects the severity of experimental periodontitis in the murine model has been investigated extensively (23, 25, 34, 48 immunized with P. gingivalis produced elevated levels of serum antibodies, and that these animals were protected against P. gingivalis-induced bone loss. Gibson and co-workers (34) showed that immunization of mice with purified RgpA could stimulate production of both P. gingivalis and RgpA-specific IgG primarily directed at the adhesion domain of RgpA. The elevated levels of this antibody coincide with protection against oral bone loss elicited by P. gingivalis. In another study, YasakiInagaki and co-workers (49) examined the ability of different recombinant peptides derived from RgpA and Kgp to induce protective antibodies against various strains of P. gingivalis. The results showed that immunization with recombinant A1 domain of RgpA not only resulted in the highest titer and the strongest reactivity to P. gingivalis whole cells, but also in high opsonization against both non-invasive and invasive strains of P. gingivalis. In addition, antibodies against the recombinant A1 domain of RgpA were found to induce strongly the killing of P. gingivalis by neutrophils. These data suggest that an antibody directed at the A1 domain of RgpA is capable of inducing a protective immune response against infection by strains of P. gingivalis. In the present study, we examined how immunization with the 70 kDa recombinant peptide of RgpA (domains A1 and A2) influences the serum titers of anti-P. gingivalis IgG1 and IgG2a before and after oral infection with P. gingivalis. Our results showed that anti-P. gingivalis IgG1 titers, but not IgG2a titers, increased significantly following immunization and pre-infection ( Fig. 3A and 3C ). As IgG1 is representative of a Th2 cytokine response (32, 33) , the high IgG1 titers found in the immunized group suggest a protective Th2 response. In contrast, IgG2a titers are significantly higher only in the heat-killed P. gingivalis-immunized mice (Fig. 3C) , with no significant differences in comparison to the non-immunized group. These results confirm those of O'BrienSimpson et al. (23) , who showed that immunization with RgpA-Kgp complexes induces high IgG1 and low IgG2a titers.
In conclusion, we are suggesting that immunization of mice with native RgpA shifts the early local immune response toward an anti-inflammatory response, which may in turn modulate the humoral response to a protective IgG1 response. The anti-inflammatory early local response, along with an elevated IgG1 response, coincides with protection against P. gingivalisinduced alveolar bone loss. Taken together, these data suggest that the 70 kDa recombinant RgpA peptide may be a good candidate for a vaccine in the prevention of P. gingivalisrelated periodontitis.
